Characteristics | Immuno-virological Discordant Responses | Total (n %)) | |
---|---|---|---|
No (n (%)) | Yes (n (%)) | ||
Gender | |||
 Male | 90 (82.6) | 19 (17.4) | 109 (100) |
 Female | 140 (92.7) | 11 (7.3) | 151 (100) |
Age (years) at 36 months median time of HAART follow up | |||
 < 39 | 122 (86.5) | 19 (13.5) | 141 (100) |
 > 39 | 108 (90.8) | 11 (9.2) | 119 (100) |
Educational level | |||
 No education | 54 (85.7) | 9 (14.3) | 63 (100) |
 Primary | 66 (83.5) | 13 (16.5) | 79 (100) |
 Secondary and above | 110 (93.2) | 8 (6.8) | 118 (100) |
Residence | |||
 Rural | 41 (83.7) | 8 (16.3) | 49 (100) |
 Urban | 189 (89.6) | 22 (10.4) | 211 (100) |
Chronic non-communicable diseasesa | |||
 Yes | 9 (75.0) | 3 (25.0) | 12 (100) |
 No | 221 (89.1) | 27 (10.9) | 248 (100) |
INH Prophylaxis given | |||
 Yes | 119 (93.0) | 9 (7.0) | 128 (100) |
 No | 111 (84.1) | 21 (15.9) | 132 (100) |
History of TB co-infection | |||
 Yes | 37 (86.0) | 6 (14.0) | 43 (100) |
 No | 193 (88.9) | 24 (11.1) | 217 (100) |
History of opportunistic infections (other than TB)b | |||
 Yes | 126 (88.1) | 17 (11.9) | 143 (100) |
 No | 104 (88.9) | 13 (11.1) | 117 (100) |
Adherence to treatment | |||
 Fair/Poor | 9 (50.0) | 9 (50.0) | 18 (100) |
 Good | 221 (91.3) | 21 (8.7) | 242 (100) |
Regimen given | |||
 TDF basedc | 179 (90.9) | 18 (9.1) | 197 (100) |
 AZT basedd | 49 (81.7) | 11 (18.3) | 60 (100) |
 ABC basede | 2 (66.7) | 1 (33.3) | 3 (100) |
Age (years) at HAART initiation | |||
 < 35 | 113 (85.6) | 19 (14.4) | 132 (100) |
 > 35 | 117 (91.4) | 11 (8.6) | 128 (100) |
WHO clinical stage at baseline | |||
 I/II | 112 (91.1) | 12 (8.9) | 124 (100) |
 III/IV | 118 (86.8) | 18 (13.2) | 136 (100) |
History of malnutrition | |||
 Yes | 68 (81.9) | 15 (18.1) | 83 (100) |
 No | 162 (91.5) | 15 (8.5) | 177 (100) |
Cotrimoxazole prophylaxis given (months) (N = 239) | |||
 < 30 | 96 (83.5) | 19 (16.5) | 115 (100) |
 > 30 | 113 (91.1) | 11 (8.9) | 124 (100) |
Viral load (copies/mL) at 36 months median time of HAART follow up | |||
 < 1000 | 221 (96.1) | 9 (3.9) | 230 (100) |
 > 1000 | 9 (30.0) | 21 (70.0) | 30 (100) |
CD4+ count (cells/μl) at baseline | |||
 < 100 | 67 (87.0) | 10 (13.0) | 77 (100) |
 101–200 | 69 (85.2) | 12 (14.8) | 81 (100) |
 201–300 | 49 (92.5) | 4 (7.5) | 53 (100) |
 > 300 | 45 (91.8) | 4 (8.2) | 49 (100) |
CD4+ count (cells/μl) at 36 months median time of HAART follow up | |||
 < 100 | 9 (56.2) | 7 (43.8) | 16 (100) |
 101–200 | 27 (79.4) | 7 (20.6) | 34 (100) |
 201–300 | 34 (81.0) | 8 (19.0) | 42 (100) |
 > 300 | 160 (95.2) | 8 (4.8) | 168 (100) |
Time interval from HIV Diagnosis to HAART initiation (months) | |||
 < 12 | 175 (87.1) | 26 (12.9) | 201 (100) |
 > 12 | 55 (93.2) | 4 (6.8) | 59 (100) |
HBV co- infection(n = 139) | |||
 Yes | 7 (63.6) | 4 (36.4) | 11 (100) |
 No | 114 (89.1) | 14 (10.9) | 128 (100) |
HCV co-infection(n = 64) | |||
 Yes | 0 (0.0) | 2 (100) | 2 (100) |
 No | 53 (85.5) | 9 (14.5) | 62 (100) |